122 related articles for article (PubMed ID: 3437071)
1. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.
Trenk D; Wagner F; Jähnchen E; Plänitz V
J Clin Pharmacol; 1987 Dec; 27(12):988-93. PubMed ID: 3437071
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients.
Kirch W; Hutt HJ; Plänitz V
J Clin Pharmacol; 1990 Dec; 30(12):1088-95. PubMed ID: 2273081
[TBL] [Abstract][Full Text] [Related]
3. Absolute bioavailability of moxonidine.
Theodor R; Weimann HJ; Weber W; Michaelis K
Eur J Drug Metab Pharmacokinet; 1991; 16(2):153-9. PubMed ID: 1936074
[TBL] [Abstract][Full Text] [Related]
4. Influence of food on the oral bioavailability of moxonidine.
Theodor RA; Weimann HJ; Weber W; Müller M; Michaelis K
Eur J Drug Metab Pharmacokinet; 1992; 17(1):61-6. PubMed ID: 1499598
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacokinetic interactions between moxonidine and digoxin.
Pabst G; Weimann HJ; Weber W
Clin Pharmacokinet; 1992 Dec; 23(6):477-81. PubMed ID: 1458765
[TBL] [Abstract][Full Text] [Related]
6. Quinidine does not affect the renal clearance of moxonidine.
Wise SD; Chan C; Schaefer HG; He MM; Pouliquen IJ; Mitchell MI
Br J Clin Pharmacol; 2002 Sep; 54(3):251-4. PubMed ID: 12236844
[TBL] [Abstract][Full Text] [Related]
7. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
Prichard BN; Graham BR
Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and disposition of the antihypertensive agent moxonidine in humans.
He MM; Abraham TL; Lindsay TJ; Schaefer HC; Pouliquen IJ; Payne C; Czeskis B; Shipley LA; Oliver SD; Mitchell MI
Drug Metab Dispos; 2003 Mar; 31(3):334-42. PubMed ID: 12584161
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
10. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
[TBL] [Abstract][Full Text] [Related]
12. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of moxonidine in Fischer 344 rats.
He MM; Abraham TL; Lindsay TJ; Chay SH; Czeskis BA; Shipley LA
Drug Metab Dispos; 2000 Apr; 28(4):446-59. PubMed ID: 10725314
[TBL] [Abstract][Full Text] [Related]
14. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
Armah BI; Hofferber E; Stenzel W
Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
17. Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.
Müller M; Weimann HJ; Eden G; Weber W; Michaelis K; Dilger C; Achtert G
Eur J Drug Metab Pharmacokinet; 1993; 18(3):277-83. PubMed ID: 8149947
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
Bareggi SR; Gambaro V; Valenti M; Benvenuti C
Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
[TBL] [Abstract][Full Text] [Related]
19. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
Ollivier JP; Christen MO
J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
